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Abstract
AIM
To determine whether oral glutathione (GSH) adminis-
tration can alleviate the effects of fasting-induced 
intestinal atrophy in the small intestinal mucosa. 
METHODS
Rats were divided into eight groups. One group was 
fed ad libitum, another was fed ad libitum and received 
oral GSH, and six groups were administrated saline 
(SA) or GSH orally during fasting. Mucosal height, 
apoptosis, and cell proliferation in the jejunum were 
histologically evaluated. iNOS protein expression 
(by immunohistochemistry), nitrite levels (by high 
performance liquid chromatography, as a measure of 
NO production), 8-hydroxydeoxyguanosine formation 
(by ELISA, indicating ROS levels), glutathione/
oxidized glutathione (GSH/GSSG) ratio (by enzymatic 
colorimetric detection), and γ-glutamyl transpeptidase 
(Ggt1) mRNA levels in the jejunum (by semi-quantitative 
RT-PCR) were also estimated.
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RESULTS
Oral GSH administration was demonstrated to 
drastically reduce fasting-induced intestinal atrophy in 
the jejunum. In particular, jejunal mucosal height was 
enhanced in GSH-treated animals compared to SA-
treated animals [527.2 ± 6.9 for 50 mg/kg GSH, 567.6 
± 5.4 for 500 mg/kg GSH vs  483.1 ± 4.9 (μm), P  < 0.01 
at 72 h]. This effect was consistent with decreasing 
changes in GSH-treated animals compared to SA-
treated animals for iNOS protein staining [0.337 ± 0.016 
for 50 mg/kg GSH, 0.317 ± 0.017 for 500 mg/kg GSH 
vs  0.430 ± 0.023 (area of staining part/area of tissue), 
P  < 0.01 at 72 h] and NO [2.99 ± 0.29 for 50 mg/kg 
GSH, 2.88 ± 0.19 for 500 mg/kg GSH vs  5.34 ± 0.35 
(nmol/g tissue), P  < 0.01 at 72 h] and ROS [3.92 ± 0.46 
for 50 mg/kg GSH, 4.58 ± 0.29 for 500 mg/kg GSH vs  
6.42 ± 0.52 (8-OHdG pg/μg DNA), P  < 0.01, P  < 0.05 
at 72 h, respectively] levels as apoptosis mediators 
in the jejunum. Furthermore, oral GSH administration 
attenuated cell proliferation decreases in the fasting 
jejunum [182.5 ± 1.9 for 500 mg/kg GSH vs  155.8 ± 
3.4 (5-BrdU positive cells/10 crypts), P  < 0.01 at 72 
h]. Notably, both GSH concentration and Ggt1 mRNA 
expression in the jejunum were also attenuated in rats 
following oral administration of GSH during fasting as 
compared with fasting alone [0.45 ± 0.12 vs  0.97 ± 0.06 
(nmol/mg tissue), P  < 0.01; 1.01 ± 0.11 vs  2.79 ± 0.39 
(Ggt1 mRNA/Gapdh mRNA), P  < 0.01 for 500 mg/kg 
GSH at 48 h, respectively].
CONCLUSION
Oral GSH administration during fasting enhances 
jejunal regenerative potential to minimize intestinal 
mucosal atrophy by diminishing fasting-mediated ROS 
generation and enterocyte apoptosis and enhancing 
cell proliferation.
Key words: Intestinal atrophy; Glutathione; Apoptosis; 
Cell proliferation; Inducible nitric oxide synthase
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: We have previously demonstrated that the 
intestinal mucosal atrophy consequent to fasting is 
due in large part to increased apoptosis in jejunal villi 
and decreased cell proliferation in jejunal crypts, with 
concomitant increased reactive oxygen species (ROS) 
and NO production and decreased glutathione (GSH). 
Here we demonstrate protection against fasting-induced 
intestinal mucosal atrophy by minimizing ROS induction 
in the intestinal mucosa through supplemental oral 
administration of an antioxidant such as GSH during 
fasting in rats. In particular, oral GSH administration 
during fasting enhances jejunal regenerative potential 
by diminishing enterocyte apoptosis and enhancing cell 
proliferation.
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INTRODUCTION
Fasting induces small intestinal mucosal atrophy 
including increased epithelial permeability and com­
promised tight junctions, which can lead to bacterial 
translocation, particularly in patients receiving a 
prolonged course of total parenteral nutrition (TPN)[1,2]. 
Many surgeons involved in nutritional support therapy 
desire the identification of bioactive substances that 
may be efficacious in protecting against intestinal injury 
during long­term TPN administration, particularly with 
respect to intestinal barrier function and subsequent 
septic complications. Fasting and other states of 
malnutrition are associated with increased reactive 
oxygen species (ROS) formation, which has been 
implicated in the loss of intestinal mucosal structure 
and function under conditions of inflammation, injury, 
and shock[3,4]. In addition, these fasting states are also 
accompanied by depletion of the critical antioxidant 
glutathione (GSH), which functions to eliminate induced 
ROS in the intestinal mucosa[5­7]. Therefore, GSH is the 
most prevalent and important low­molecular­weight 
thiol in mammalian tissues[8]. As GSH deficiency in 
tissues is associated with increased oxidative stress, 
aging, and increased risk of numerous chronic diseases 
as well as fasting[9], the maintenance of tissue levels 
of GSH is critical for maintaining health and preventing 
disease and age­related biological insults.
GSH sources in the intestinal mucosa include 
intracellular synthesis, biliary supply, and dietary 
intake. The intestinal lumen receives a large quantity 
of hepatic GSH from biliary secretion[10] and dietary 
GSH from fresh fruits, vegetables, and many types of 
meat[11]. As the only enzyme of the γ­glutamyl cycle 
located on the outer surface of the plasma membrane, 
γ­glutamyl transpeptidase (GGT) plays a key role in 
GSH homeostasis by breaking down extracellular GSH 
and providing cysteine, the rate­limiting substrate 
for intracellular de novo GSH synthesis[12]. The two 
intracellular enzymes, γ­glutamylcysteine synthetase 
and GSH synthetase, catalyze intracellular GSH 
synthesis from glutamate, cysteine, and glycine, which 
are translocated into cells by amino acid transporters 
on the surface of the plasma membrane following the 
resolution of extracellular GSH by GGT. Intracellular 
GSH plays an important role in antioxidant defense 
and the regulation of pathways essential for in vivo 
homeostasis through its catalysis by glutathione 
S­transferase (GST) and glutathione peroxidase[9]. 
Studies of oral GSH supplementation in humans and 
laboratory animals have shown that the enhance­
ment of intestinal mucosal GSH levels by oral GSH 
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supplementation under conditions in which intracellular 
GSH status is compromised (i.e., GSH deficiency-related 
biological insults) can restore tissue GSH and promote 
ROS metabolism[10,13,14]. Thus, it has been described 
that orally administered GSH acts as backup for GSH­
deficient tissue.
As an alternative, the ability to control extracellular 
redox provides another possible role for intestinal 
luminal GSH. Recent studies have shown that the thiol/
disulfide redox status in the extracellular compartment 
regulates the ROS that are generated primarily in 
the intracellular compartment and serve an important 
function in the activation of proteins and up­regulation 
of antioxidant and detoxification systems[15­17]. Fur­
thermore, many proteins including transporters, 
receptors, and enzymes present on the surface of 
the plasma membrane and located in extracellular 
fluids contain cysteine and methionine residues that 
are subject to oxidation. Accordingly, these proteins 
respond to variations in the extracellular thiol/disulfide 
redox environment, which can alter their activity[18]. 
Notably, recent demonstrations that treatment with 
GSH leads to a significant increase in the number of free 
sulfhydryls on the cell surface have led to the conclusion 
that extracellular GSH modulates the interaction 
between bacteria and epithelial respiratory cells and 
inhibits bacterial invasion into these cells[19]. 
We previously suggested that fasting for 2­3 d 
causes intestinal mucosal atrophy resulting from 
increased apoptosis in jejunal villi, nitric oxide (NO) 
and ROS production following elevated inducible nitric 
oxide synthase (iNOS) expression, and decreased cell 
proliferation in jejunal crypts[20]. Conversely, these 
apoptosis mediators are all suppressed by treatment 
with aminoguanidine, a selective iNOS inhibitor, with 
consequent mucosal recovery, suggesting that iNOS, 
which induces the production of ROS, is likely to 
constitute a significant upstream factor promoting 
fasting­induced apoptosis in enterocytes. Furthermore, 
refeeding repaired fasting­induced jejunal atrophy by 
inhibiting these apoptosis mediators, including ROS, 
and also showed an association between ROS inhibition 
and increased cell proliferation for decreasing intestinal 
mucosal atrophy[21]. Therefore, we hypothesized that 
protection against intestinal mucosal atrophy might be 
provided through the elimination of induced ROS in the 
intestinal mucosa by introducing an antioxidant such 
as GSH during a fasting period in rats.
Therefore, the objective of the present study was 
to investigate the effects of oral GSH administration 
on the manifestation of fasting­induced intestinal 
atrophy through the reduction of oxidative stress, with 
a particular focus on the possible participation of intra­
cellular GSH levels and GGT expression on the cell 
surface as parameters for de novo intracellular GSH 
synthesis.
MATERIALS AND METHODS
Animals and experimental design
The experimental protocol and design were approved 
by the Institutional Animal Care and Use Committee at 
the Life Science Center of Josai University. Male Wistar 
rats at 9 wk of age were purchased from SLC (Shizuoka, 
Japan) and housed in wire­bottomed cages. The rats 
were placed in a room illuminated from 7:00 am to 
7:00 pm (12:12­h light:dark cycle). The animals were 
allowed free access to deionized water and standard 
rat chow (CE­2, CLEA Japan) until the study began. At 
10 wk of age, 59 rats were randomly divided into eight 
groups (Figure 1). Each group received saline (SA) 
or GSH (50 or 500 mg/kg b.w./d) using oral gavage 
needles at 24, 48, and 72 h before fasting, including 
a normally fed control group and a normally fed 
control that received GSH, with the following fasting 
durations in each group: (1) SA + ad libitum (normal 
fed control); (2) SA + 48­h fast; (3) SA + 72­h fast; 
(4) 500 mg/kg GSH + ad libitum (normal fed control 
received GSH); (5) 50 mg/kg GSH + 48­h fast; (6) 50 
mg/kg GSH + 72­h fast; (7) 500 mg/kg GSH + 48­h 
fast; and (8) 500 mg/kg GSH + 72­h fast. All rats 
received SA or GSH by oral gavage for 2, 26, and 50 
h after fasting. The GSH (Setria® reduced glutathione) 
used in this work was provided by Kyowa Hakko Bio 
Co., Ltd. The rats were weighed daily.
Collection of intestinal mucosa
After fasting, the rats were anesthetized and then 
euthanized by exsanguination. The entire small intestine 
was carefully removed and placed on ice. Then, 10 cm 
of tissue from the oral (duodenum) side was removed 
and the remainder of the intestine was divided into two 
segments: proximal (jejunum) and distal (ileum). The 
segments used in analyses comprised the jejunum from 
3 to 5 cm distal to the duodenum[22]. Samples with a 
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ad libitum 
(normal fed control received GSH)
ad libitum
48 h fast 
72 h fast 
ad libitum (normal fed control)
48 h fast 
72 h fast 
48 h fast 
72 h fast 
ad libitum
(50 mg)
ad libitum
(500 mg)
SA
GSH
                                0 h               24 h            48 h            72 h
                                                 Fasting
Figure 1  Experimental design. Rats were divided into eight groups, one of 
which was fed ad libitum, another of which was fed ad libitum and received 
oral glutathione (GSH), and six of which were administered saline (SA) or GSH 
orally prior to and after fasting. The large block arrows represent treatment with 
SA (closed gray arrow) and GSH (closed block arrow).
-72 h    -48 h  -24 h      2 h               26 h             50 h
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and examined under a light microscope and a digital 
camera system. For each rat, 5 clearly dyed sections 
were chosen randomly and 5 random fields for each 
section were assessed (at 40 × magnification). The 
content of iNOS was quantitatively measured based 
on the average optical density using a digital camera 
and ImageJ software (National Institutes of Health, 
Bethesda, Maryland, United States)[26].
To assess cell proliferation in the crypt, the cell 
proliferation index was determined using conventional 
light microscopy of specimens immunohistochemically 
stained for 5­BrdU[27]. Rats were intraperitoneally 
injected with 100 mg/kg 5­BrdU prior to euthanasia. 
After paraffin embedding and sectioning, tissue 
sections were dewaxed and immersed in 3% hydrogen 
peroxide­methanol solution. The specimens were 
washed with PBS and denatured in 2 N hydrochloric 
acid. Following further PBS washing, the specimens 
were immersed in 0.1 mol/L boric acid buffer (pH 8.5), 
incubated with 20 μg/mL proteinase K at 37 ℃, and 
then the reaction was terminated with PBS containing 
bovine serum albumin. The sections were incubated 
with a mouse anti­5­BrdU monoclonal antibody (1:50; 
Chemicon International, Billerica, MA, United States), 
with the exception of control samples, for which the 
primary antibody was omitted. A biotinylated goat 
anti­mouse IgG (1:200; Vector Laboratories) was 
used as a secondary antibody. The sections were then 
treated using the VECTASTAIN Elite ABC Kit (Vector 
Laboratories) and antibody binding was detected by 
color development after addition of diaminobenzidine. 
Finally, the sections were counterstained with hemato­
xylin and examined under a light microscope with a 
digital camera system. The number of labeled cells 
in at least 10 well­oriented longitudinal crypts was 
determined for each rat. Results are expressed as the 
number of 5­BrdU­labeled cells per crypt.
Jejunal nitrite concentrations
Nitrite concentrations in the jejunum were measured 
using a dedicated high­performance liquid chromato­
graphy (HPLC) system (ENO­20; EiCom, Kyoto, 
Japan)[28]. Jejunal segments were homogenized with 
an equal volume of methanol and centrifuged for 
deproteinization at 12000 g at 4 ℃ for 5 min. The 
samples were then applied to the HPLC system. The 
nitrites and nitrates were separated using a reverse­
phase column (NO­PAK; EiCom), after which nitrate 
was reduced to nitrite in a reduction column packed 
with copperized cadmium (NO­RED; EiCom). These 
nitrites were then mixed with the Griess reagent in 
a reaction coil and the change in absorbance was 
monitored at 540 nm.
DNA oxidation analysis
Oxidative stress in the jejunum was evaluated by 
quantifying 8­hydroxydeoxyguanosine (8­OHdG) 
present in DNA[29]. 8­OHdG is a product of oxidative 
length of approximately 3 cm were fixed in 10% neutral 
buffered formalin for measurement of mucosal height 
and immunohistochemistry. The remaining segments 
were snap­frozen in liquid nitrogen and stored at ­80 ℃.
Histopathological analysis of mucosal height and 
apoptotic index
Fixed tissue samples were embedded in paraffin and 
sectioned (2­3 μm thickness) prior to being stained 
with hematoxylin and eosin (H&E). Mucosal height 
(villous height plus crypt depth) was measured using 
a microscope (BX41; Olympus, Tokyo, Japan) and a 
digital camera system (Penguin 150CL; Pixera, San 
Jose, CA, United States). Mucosal height was measured 
for at least 30 villi per animal.
To detect enterocyte apoptosis in the jejunum, 
apoptotic index (AI) using conventional light microscopy 
of H&E­stained specimens was used. We followed 
previously published methods[20,23]. In brief, jejunal 
sections as used above for histopathological analysis 
were examined in a blinded manner for the typical 
attributes of apoptotic cells. We assessed 50 villus­crypt 
columns per rat. For each column, the number and 
position of apoptotic cells and the total number of cells 
were recorded. To account for the effects of fasting and 
GSH treatment on apoptosis, the average number of 
apoptotic cells in villi and crypts was determined along 
with AI. To identify the locations of apoptosis along the 
villi and crypts, AI distribution curves were constructed 
on the basis of group means, in which cell position vs 
AI was plotted at each position. Here, AI was defined as 
the total number of apoptotic cells at each cell position 
and is expressed as the percentage of the total number 
of cells counted at that cell position. Cell position 1 was 
set as the cell at the crypt­villus junction and the cell at 
the base of the crypt column for villus and crypt data, 
respectively.
Immunohistochemical assessment of iNOS expression 
and 5-bromo-2’-deoxyuridine (5-BrdU)-positive cells
Immunohistochemical staining was performed using a 
rabbit anti­iNOS polyclonal antibody[24]. The specimens 
were dewaxed and treated for antigen retrieval by 
boiling in 10 mmol/L citrate buffer (pH 6.0)[25]. After 
being washed with PBS, the specimens were incubated 
in 6% hydrogen peroxide and nonspecific binding 
was blocked with a 20% goat serum solution in PBS. 
Specimens were subsequently incubated with an 
anti­iNOS primary antibody (1:100; BD Transduction 
Laboratories, Lexington, KY, United States), except for 
the control sections, for which no primary antibody 
was used. A biotinylated goat anti­rabbit IgG (1:200; 
Vector Laboratories, Burlingame, CA, United States) 
was used as a secondary antibody. The sections were 
then treated using the VECTASTAIN Elite ABC Kit (Vector 
Laboratories), and reaction products were detected 
using color development with diaminobenzidine. Finally, 
the sections were counterstained with hematoxylin 
Uchida H et al . Jejunal atrophic reduction by oral glutathione
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DNA damage following specific enzymatic cleavage 
after 8­hydroxylation of the guanine base and is 
thought to constitute a marker of oxidative DNA 
damage, reflecting the DNA repair rate[30]. Jejunal DNA 
was purified using the DNA Extractor TIS Kit (Wako 
Pure Chemical Industries Ltd., Osaka, Japan)[31]. DNA 
samples were hydrolyzed to nucleosides by sequential 
incubation with 6 U of nuclease P1 (Wako) followed 
by 2 U of alkaline phosphatase (Wako). Hydrolysates 
were filtered through a VIVASPIN 500 MWCO 10000 
filter (Sartorius Stedim Biotech, Gottingen, Germany). 
The levels of 8­OHdG in the filtered samples were 
determined using an ELISA kit (Japan Institute for the 
Control of Aging, Shizuoka, Japan).
Jejunal GSH and GSSG concentrations
GSH and GSSG concentrations were measured by using 
a GSSG/GSH Quantification Kit (Dojindo Molecular 
Technologies, Inc., Rockville, MD, United States). 
Jejunal segments were homogenized with 5% sodium 
sulfosalicylate (Wako) and centrifuged to remove 
proteins. For each sample, the supernatant was added 
to a well to which coenzyme working solution and 
enzyme working solution had been previously added, 
and incubated at room temperature. Then, the sub­
strate working solution was added to the well and it 
was incubated at room temperature. The absorbance of 
samples and the GSH standard was measured at 405 
nm using a microplate reader (TECAN GENios, Grodig, 
Austria). For measurement of GSSG, the supernatant 
was treated with masking solution and then added to 
a well as described above. The absorbance of samples 
and standard GSSG was measured at 405 nm.
Analysis of Ggt1 mRNA expression by semi-quantitative 
reverse transcription-PCR
Total RNA was purified using the TaKaRa RNAiso Reagent 
(TaKaRa Bio, Kusatsu, Japan). Reverse transcription (RT)­
PCR was performed with total RNA using the RNA PCR 
kit (AMV) Version 3.0 (TaKaRa Bio): 1 cycle at 42 ℃ for 
30 min, 99 ℃ for 5 min, and 5 ℃ for 5 min for reverse 
transcription, and 30 cycles at 94 ℃ for 30 s, 60 ℃ for 
30 s, and 72 ℃ for 1 min for PCR. The following primer 
pairs (synthesized by TaKaRa Bio) were used: Ggt1 
forward primer, 5’­ACCACTCACCCAACCGCCTAC­3’; 
Ggt1 reverse, 5’­ATCCGAACCTTGCCGTCCTT­3’ 
(product size: 317 bp)[12]. Expression of target mRNAs 
was measured relative to that of glyceraldehyde 
3­phosphate dehydrogenase (Gapdh), which was 
determined using the following primers: Gapdh 
forward, 5’­GGCACAGTCAAGGCTGAGAATG­3’; Gapdh 
reverse, 5’­ATGGTGGTGAAGACGCCAGTA­3’ (143 bp, 
TaKaRa Bio ID: RA015380). A portion of each PCR 
mixture was electrophoresed on a 2% agarose gel in 
Tris­borate­EDTA buffer and DNA bands were visualized 
using ethidium bromide staining. PCR product intensity 
was measured using the Gene Genius Bioimaging 
System (Syngene, Cambridge, United Kingdom).
Statistical analysis
Statistical analyses were performed using SPSS ver. 
22 for Windows. All values are expressed as the mean 
± SE. One­way analysis of variance (ANOVA) followed 
by a Bonferroni multiple­comparison test was used 
for analyzing the statistical difference between the 
fasting periods in SA­ or GSH­treated groups. Two­way 
ANOVA followed by a Bonferroni multiple­comparison 
test was used for analyzing the statistical difference 
between the SA­ and GSH­treated groups for the 
fasting periods. Statistical significance was accepted 
at P < 0.05. The statistical analysis of this study was 
performed by Uchida H, who acquired biostatistics 
expertise during his training in public health.
RESULTS
Body weight changes
Figure 2 shows body weight changes in SA­treated 
and GSH­treated rats. Decreases in body weight in 
both groups were observed along with fasting. Rats 
fasted for 48 and 72 h with SA treatment showed 
approximately 15% (P < 0.01) and 19% (P < 0.01) 
body weight loss, respectively, compared with normally 
fed controls. There was no difference in weight loss 
between the GSH treatments and the respective SA­
treated groups at each fasting period.
Histological characterization of jejunal mucosal atrophy
Jejunal mucosal atrophy was assessed by jejunal 
mucosal height. Decreased jejunal mucosal height in 
both SA­ and GSH­treated rats was observed along 
with fasting (Figure 3). Rats fasted for 48 and 72 h 
with SA treatment showed a significant decrease (P < 
0.01) in mucosal height compared with normally fed 
controls. However, significant differences (P < 0.01) 
in jejunal mucosal height were found between the SA­ 
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Figure 2  Effects of fasting and glutathione treatment on body weight. 
Fasting caused gradual decreases in body weight in both SA- and GSH-treated 
groups. There was no difference in weight loss between the GSH treatments 
and the respective SA-treated groups in each fasting period. Values represent 
the mean ± SE. bP < 0.01 vs the normally fed control. 7-8 rats were tested in 
each group. GSH: Glutathione; SA: Saline.
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and GSH­treated rats with 48 and 72 h of fasting.
iNOS protein expression in the jejunum
As shown in Figure 4A, iNOS protein staining was 
localized almost exclusively in the mucosal epithelial 
monolayer in the 48­ and 72­h fasting periods compared 
with the normally fed controls, and a decreased level 
of staining occurred with GSH treatment. Quanti­
tative measurement using the average optical density 
revealed that this expression significantly increased 
following fasting for 48 and 72 h with SA treatment (P < 
0.01), whereas GSH treatments significantly decreased 
the fasting­induced enhancement of jejunal iNOS 
protein expression (P < 0.05 vs SA at 48 h fasting, P < 
0.01 vs SA at 72 h fasting; Figure 4B).
Nitrite level in the jejunum
We next measured the levels of nitrite, which is a stable 
oxidation product of endogenous NO that is induced 
by iNOS. In SA­treated groups, fasting significantly 
increased the jejunal nitrite concentration with 48 
and 72 h of fasting compared with the normally fed 
controls (P < 0.01; Figure 5). Conversely, GSH treat­
ments significantly decreased the fasting­induced 
enhancement of the jejunal nitrite concentration com­
pared with the respective SA­treated group for each 
fasting period (P < 0.01). 
8-OHdG level in the jejunum
As we previously determined that fasting causes jejunal 
apoptosis via ROS production and induction of NO 
following increased iNOS expression, in the present 
study we measured levels of iNOS expression, nitrite 
(indicating NO production), and 8­OHdG (as a marker 
of ROS presence). Consistent with the abovementioned 
changes in iNOS expression, fasting increased intestinal 
nitrite levels, whereas the degree of increase was 
significantly reduced by GSH treatment. Furthermore, 
the elevated jejunal 8­OHdG levels observed after 
fasting were significantly diminished by both 48 h and 
72 h of GSH treatment (P < 0.01 for 50 mg/kg GSH vs 
SA with 72 h of fasting, P < 0.05 for 500 mg/kg GSH vs 
SA with 72 h of fasting; Figure 6). 
Evaluation of enterocyte apoptosis
Apoptosis was determined by histomorphometry, which 
is preferable to terminal deoxynucleotidyl transferase 
dUTP nick­end labeling for quantitative assessment. 
Using histomorphometric assessment of jejunal cells, 
we evaluated the contribution of reduced apoptosis to 
the recovery from fasting­induced mucosal atrophy 
mediated by oral GSH treatment. The representative 
apoptosis changes as visualized by conventional light 
microscopy of H&E­stained specimens are shown 
in Figure 7A. AI distribution profiles in the villi and 
the crypt are also shown in Figure 7B. From the AI 
distribution profiles, increased apoptosis in the lower 
half of the villus (cell positions 1 to 40) was evident 
with 48 and 72 h of fasting in the SA­treated groups, 
and this increase was diminished by GSH treatment. In 
the SA-treated groups, fasting significantly increased 
jejunal villus AI with 48 and 72 h of fasting compared 
with that in the normally fed controls (P < 0.01; Table 
1). GSH treatment significantly decreased the fasting-
induced enhancement of villus AI compared with that 
in the respective SA­treated group for each fasting 
period (P < 0.05 for 50 mg/kg GSH vs SA with 48 or 
72 h of fasting, P < 0.01 for 500 mg/kg GSH vs SA 
with 48 or 72 h of fasting). From the AI distribution 
profiles, increased apoptosis in the lower two-thirds of 
crypts (cell positions 1 to 20) was evident with 48 and 
72 h of fasting in the SA­treated groups (Figure 7B), 
and this effect was diminished by GSH treatment. In 
the SA-treated groups, fasting significantly increased 
jejunal crypt AIs with 48 and 72 h of fasting compared 
with the normally fed controls (P < 0.01; Table 1). 
GSH treatments significantly ameliorated the fasting-
induced increase in crypt AI compared with the 
respective SA­treated group for each fasting period (P 
< 0.01).
Evaluation of cell proliferation
GSH is known to exhibit an important function related 
to the regulation of cell proliferation by protecting 
against the damaging effects of ROS[32]. To evaluate 
the effect of oral GSH administration on the reduced 
cell proliferation in fasting­induced jejunal mucosal 
atrophy, we assessed 5­BrdU incorporation, a pro­
liferation indicator, in the jejunum. Although cell 
proliferation decreased with 48 and 72 h of fasting 
compared with that in the normally fed controls (P < 
0.01; Figure 8), animals treated with GSH exhibited 
significantly higher levels of jejunal cell proliferation 
compared with those in the respective SA­treated 
group for each fasting period (P < 0.01 for 50 mg/kg 
GSH vs SA at 48 h fasting, and for 500 mg/kg GSH vs 
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Figure 3  Effects of fasting and glutathione treatment on jejunal mucosal 
atrophy. Jejunal mucosal atrophy was assessed by jejunal mucosal height. 
Values represent the mean ± SE. bP < 0.01 vs the normally fed control. dP < 0.01 
vs the respective SA-treated group in each fasting period. 7-8 rats were tested 
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SA at 48 and 72 h fasting). 
GSH and GSSG levels in the jejunum
GSH is one of the most important scavengers of ROS; 
additionally, GSH and oxidized GSH (i.e., GSSG) are 
used as markers of oxidative stress[33]. To evaluate 
GSH redox balance and GSH levels in the jejunum 
consequent to oral GSH administration during fasting, 
we assessed GSH and GSSG levels in the jejunum. 
Fasting significantly decreased the GSH concentration 
in the jejunum (P < 0.01; Figure 9A). GSH treatment 
significantly further decreased the fasting­induced 
decreases in the jejunal GSH concentration for each 
fasting period (P < 0.01). Conversely, GSSG con­
centration in the jejunum was similar to that of normally 
fed controls except for the 500 mg/kg GSH treatment 
group with ad libitum feeding (Figure 9B).
Ggt1 mRNA expression in the jejunum
Fasting significantly increased Ggt1 expression in the 
jejunum at 48 h of fasting (P < 0.05) (Figure 10) 
whereas GSH treatment significantly reduced Ggt1 
elevation at 48 h of fasting (P < 0.05, P < 0.01 for 50 
mg/kg GSH, 500 mg/kg GSH vs SA at 48 h of fasting, 
respectively). A similar tendency was obtained for the 
72­h fasting group, although this difference did not 
reach statistical significance. 
DISCUSSION
Previous reports have suggested the involvement of 
GSH in fasting­induced intestinal mucosal atrophy; in 
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Figure 4  Effects of fasting and glutathione treatment on inducible nitric oxide synthase protein expression in the jejunum. A: Light micrographs of 
immunohistochemical staining for iNOS. In SA-treated groups, iNOS protein staining was localized almost exclusively in the mucosal epithelial monolayer with 48 
and 72 h of fasting compared with the normally fed control. Decreased staining occurred with GSH treatment. Bar = 100 μm. B: Optical density of iNOS protein. The 
content of iNOS protein was quantitatively measured by averaging the optical density. Values represent the mean ± SE. bP < 0.01 vs normally fed controls. dP < 0.01, 
cP < 0.05 vs the respective SA group in each fasting period. 7-8 rats were tested in each group. GSH: Glutathione; SA: Saline; iNOS: Inducible nitric oxide synthase.
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addition, fasting has been associated with increased 
ROS formation and depletion of the critical antioxidant 
GSH in the intestine[4,6,34­36]. However, the roles of GSH 
in intestinal mucosal recovery from this condition as 
mediated by oral GSH administration have not yet 
been described. The objective of the present study was 
to investigate the effects of oral GSH administration on 
the development of fasting­induced intestinal atrophy, 
with a particular focus on the possible participation of 
intracellular GSH level and GGT expression on the cell 
surface as potential parameters of intracellular de novo 
GSH synthesis.
During fasting, the intestinal lumen receives very 
little or no GSH from two of the three primary sources, 
i.e., biliary secretion[10,37] and dietary intake[11]. There­
fore, the overall GSH levels of the intestinal mucosa 
decrease during fasting because the remaining GSH 
source, intracellular GSH, is primarily synthesized from 
GSH in the intestinal lumen. 
There is growing evidence that dysfunctional 
GSH homeostasis is involved in the etiology of 
several diseases. The previously reported conditions 
associated with GSH depletion include liver disease[38], 
immune disorders[39], neurodegenerative disease[40], 
cardiovascular disease[41], pulmonary disease[42], 
arthritis, diabetes[43], and the aging process itself[44]. 
Thus, oral supplementation with GSH to increase the 
depressed GSH level has been studied extensively as a 
potential means to prevent these diseases by countering 
the negative effects of oxidative stress, which is one of 
their underlying causes. Several studies have shown that 
GSH supplementation in laboratory animals is effective, 
with benefits including enhancement of immune 
function[45] and protection against carcinogenesis[46]. 
In addition, daily consumption of GSH supplements in 
humans was effective at increasing body compartment 
stores of GSH, which may be of importance as the 
maintenance of tissue levels of GSH might be critical 
for maintaining health and preventing disease as well 
as age­related biological insults[47]. Thus, it has been 
Table 1  Enterocyte apoptosis of the jejunal villus and crypt evaluated by conventional light microscopy of hematoxylin and eosin-
stained specimens
SA 500 GSH 48 h fast 72 h fast
SA 50 GSH 500 GSH SA 50 GSH 500 GSH
Villus
   Cells per villus column, n 70 ± 1 69 ± 1 56 ± 2b 64 ± 1d 67 ± 2d 56 ± 2b 63 ± 1d 65 ± 2d
   Apoptotic cells per villus 
   column, n
  0.06 ± 0.01   0.09 ± 0.01   0.20 ± 0.03b   0.12 ± 0.01d   0.11 ± 0.01d   0.23 ± 0.03b 0.18 ± 0.01   0.14 ± 0.02c
   Apoptotic index, %   0.09 ± 0.01   0.12 ± 0.01   0.38 ± 0.06b   0.19 ± 0.02c   0.18 ± 0.02d   0.42 ± 0.06b   0.29 ± 0.02c   0.21 ± 0.02d
Crypt
   Cells per villus column, n    28 ± 0.2    27 ± 0.4    22 ± 0.4b    25 ± 0.3d    27 ± 0.4d    22 ± 0.3b    23 ± 0.4c    26 ± 0.3d
   Apoptotic cells per villus 
   column, n
  0.06 ± 0.01   0.06 ± 0.01   0.18 ± 0.01b   0.08 ± 0.01d    0.09 ± 0.01d   0.17 ± 0.02b   0.10 ± 0.01d   0.11 ± 0.01d
   Apoptotic index, %   0.21 ± 0.04   0.22 ± 0.02   0.81 ± 0.05b   0.32 ± 0.03d   0.33 ± 0.03d   0.78 ± 0.10b   0.41 ± 0.06d   0.40 ± 0.05d
Apoptosis was measured as in Figure 7A. 7-8 rats were tested in each group. Values represent the mean ± SE. bP < 0.01 vs the normally fed control; dP < 0.01 
or cP < 0.05 vs the SA-treated group in each fasting period. GSH: Glutathione; SA: Saline.
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Figure 7  Effects of fasting and glutathione treatment on apoptotic index in the jejunal villus and crypt. Representative apoptotic changes determined by 
conventional light microscopy of hematoxylin and eosin (HE)-stained sections of the jejunal mucosa are shown in A. Left side: A jejunal villus from a 72-h fasted rat 
with 500 mg/kg GSH treatment. Apoptotic cells in the villus are indicated by an arrow showing an apoptotic corpuscle (a) and condensed chromatin (b). Bar = 100 μm 
(low magnification). Bar = 20 μm (high magnification). Right side: Jejunal crypts from 48- and 72-h fasted rats. Apoptotic cells in the crypt are indicated by an arrow 
showing an intensely eosinophilic cytoplasm and nuclear fragmentation (c) and condensed chromatin (d). Bar = 20 μm. AI distribution curves in the villus and the crypt 
are shown in B. AI is defined as the total number of apoptotic cells at each cell position and is expressed as a percentage of the total number of cells counted at that 
cell position. Cell position 1 is defined as the cell at the crypt-villus junction and the cell at the base of the crypt column for the villus and crypt data, respectively. 7-8 
rats were tested in each group. GSH: Glutathione; SA: Saline.
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suggested that orally administered GSH may act as a 
backup for intracellular GSH for GSH­deficient tissue. 
Therefore, the enhancement of intestinal mucosal GSH 
levels by oral GSH supplementation under conditions 
of intracellular GSH deficiency-related biological insults 
such as fasting may restore tissue GSH and promote 
ROS metabolism, thus facilitating the recovery from 
intestinal mucosal atrophy.
Our previous studies suggested that fasting­
induced intestinal mucosal atrophy could be alleviated 
by directly inhibiting the fasting­mediated NO 
production by iNOS and subsequent ROS enhancement 
associated with increased jejunal apoptosis via, e.g., 
iNOS inhibitor treatment[20] or refeeding[21]. Notably, 
an association was also observed between inhibition of 
ROS and increasing cell proliferation[21]. The intestinal 
epithelial layer is uniquely organized for rapid self­
renewal, which is achieved by the well­regulated 
processes of crypt­to­villus apoptosis and crypt stem 
cell proliferation. The intestinal epithelium sits at 
the interface between the intestinal mucosa and the 
intestinal lumen, and as such is prone to oxidative 
damage induced by luminal and intracellular oxidants. 
A previous study[16] reviewed the GSH/GSSG redox 
mechanism, which modulates intestinal cell transition 
through cell proliferation, differentiation, or apoptosis 
and can govern the regenerative potential of the 
intestinal mucosa. Therefore, we hypothesized that 
protection against intestinal mucosal atrophy could be 
provided by controlling apoptosis and cell proliferation 
through the elimination of induced ROS in the intestinal 
mucosa by orally administering an antioxidant such as 
GSH during fasting in rats.
Here, we found that there was no difference in 
weight loss between fasting alone and oral GSH treat­
ment during fasting (Figure 2) with the GSH levels 
used for this study. Conversely, jejunal mucosal 
atrophy was significantly increased by fasting but was 
remedied by oral GSH treatment during fasting (Figure 
3), with significantly greater improvement resulting 
from the high vs low GSH dose. Furthermore, because 
the etiology of fasting­induced intestinal atrophy was 
shown to comprise ROS genesis from the NO produced 
by iNOS[20,21], we measured iNOS protein expression 
in the jejunum. We identified an inverse relationship 
between intestinal mucosal atrophy and iNOS protein 
expression (primarily in the mucosal epithelial mono­
layer) associated with oral GSH treatment during 
fasting, most particularly with high levels of GSH 
administration (Figure 4). This is supported by our 
previous observations that iNOS inhibitor treatment 
during fasting and refeeding after fasting decreases 
fasting­induced atrophy and suppresses iNOS ex­
pression in the jejunum.
Oral GSH treatment during fasting inhibited the 
fasting­mediated generation of the apoptosis me­
diators NO and ROS concomitant with decreased 
iNOS expression (Figures 5 and 6). To determine the 
importance of apoptotic changes in the jejunum for 
intestinal recovery by oral GSH treatment (Figure 
7A), we performed a histomorphometric assessment 
including AI score (Table 1) and distribution profiles 
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Figure 9  Effects of fasting and glutathione treatment on glutathione 
and oxidized glutathione concentration in the jejunum. GSH and GSSG 
concentration in the jejunum was determined by measuring the absorption 
derived from a colorimetric reaction with DTNB [5, 5’-dithiobis (2-nitrobenzoic 
acid)] coupled with the enzymatic recycling system. A: GSH concentration in the 
jejunum; B: GSSG concentration in the jejunum. Values are the mean ± SE. bP 
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(Figure 7B). The increased AI recorded in the villi and 
crypts after fasting decreased with oral GSH treatment 
(Table 1). Specifically, the lower half of the apoptotic 
enterocytes distributed across the entire jejunal villi 
and the apoptotic cells primarily located in the lower 
two­thirds of the crypt (Figure 7B) were particularly 
affected by oral GSH treatment during fasting. These 
results were broadly consistent with changes in iNOS, 
NO, and ROS as apoptosis mediators, suggesting that 
oral GSH administration during fasting may inhibit 
enterocyte apoptosis by diminishing the ROS in the 
jejunum generated by fasting.
GSH treatment also was found to alleviate the 
decreased jejunal cell proliferation mediated by fasting 
(Figure 8), with significantly greater improvement 
in fasting­induced jejunal mucosal atrophy resulting 
from high vs low dose GSH. These observations are 
consistent with the role of GSH in cell proliferation 
through protection against damage from ROS[16,32]. 
Together, these findings indicate that oral GSH admini-
stration leads to less fasting­mediated enhancement 
and therefore decreased overall ROS levels in the 
jejunal mucosa, thereby functioning to increase cell 
proliferation. This suggests that oral GSH administration 
may provide regenerative potential to the mucosa 
during fasting.
Notably, although our findings replicated prior 
results[6,34­36] that fasting significantly decreased jejunal 
GSH concentrations (Figure 9A), we found that the 
concentrations were further significantly decreased 
by oral GSH supplementation during fasting, with a 
greater effect from high vs low GSH dose. Conversely, 
the jejunal concentrations of the GSH oxidation pro­
duct GSSG were not changed by any feeding regime 
(Figure 9B). Furthermore, oral GSH treatment during 
fasting significantly decreased the fasting­induced 
ROS levels in the jejunum (Figure 6), but we consider 
it unlikely that this effect depends on antioxidant 
activity given the depressed GSH concentration in the 
jejunum. These results demonstrate that oral GSH 
administration during fasting did not contribute to 
the supply of GSH in the jejunum, and an increase in 
GSH oxidation was not observed, suggesting that oral 
GSH administration during fasting does not provide a 
backup for the jejunum­depleted GSH.
The synthesis of intracellular de novo GSH, 
which is critical for ROS removal and maintenance of 
GSH homeostasis, relies upon the enzyme activity 
of the plasma membrane protein GGT to break 
down extracellular GSH[12]. In the present study, we 
demonstrated that oral GSH treatment significantly 
ameliorated the increased jejunal Ggt1 mRNA 
expression observed following 48 h of fasting (Figure 
10). In comparison, Jonas et al[4] indicated that fasting 
for 72 h did not change Ggt1 mRNA levels in the 
ileum, although this was determined via ribonuclease 
protection assay rather than by semi­quantitative RT­
PCR as used in the present study. The different findings 
may also be a consequence of the disparity in fasting 
duration. Notably, Ogasawara et al[34] showed that 
starvation causes a striking decrease of GGT activity 
in the jejunum, which is consistent with our finding of 
fasting­induced increases in Ggt1 mRNA levels, as the 
mRNA expression of GGT might be upregulated by the 
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decline of GGT activity[12]. Furthermore, Zhang et al[12] 
described that Ggt1 mRNA expression is increased 
during oxidative stress, which was considered to 
constitute an adaptation to such adverse conditions. 
Similarly, we found that fasting increased jejunal ROS 
levels and up­regulated Ggt1 mRNA expression in the 
jejunum in this study. However, considering that oral 
GSH treatment during fasting significantly decreased 
both jejunal GSH concentration and Ggt1 mRNA 
expression, the supplemented GSH in the intestinal 
lumen may not be involved in intracellular de novo GSH 
synthesis.
The ability of GSH to control extracellular redox 
provides another possible role for intestinal luminal 
GSH during fasting, as the present study demonstrated 
that intracellular GSH levels of the jejunum mucosa 
were not increased by intestinal luminal GSH ad­
ministration during fasting, although the GSH ad­
ministration attenuated the fasting­induced ROS in 
the intestinal mucosa. Reversible redox reactions of 
intracellular thiol/disulfide pairs such as GSH/GSSG 
regulate diverse biological processes in vivo, including 
signaling for apoptosis and cell proliferation, enzyme 
catalysis, gene expression, and molecular folding and 
trafficking[16­18,48,49]. Most studies have focused on the 
major intracellular thiols such as GSH[50,51]; however, 
relatively little is known regarding the effects of changes 
in extracellular thiol/disulfide pairs. Biliary GSH is 
an important intestinal luminal source of GSH and 
attenuates ROS of the intestinal mucosa by increasing 
the GSH levels of the intestinal mucosa. However, 
it has been suggested that biliary GSH controls the 
status of the intestinal lumen and contributes to 
protection of the intestinal mucosa[10]. The GSH of 
the intestinal lumen may act on the intestinal mucosa 
via both of these two pathways, and it is important 
to consider the control of the redox status of the 
intestinal lumen. In addition, the roles of extracellular 
(i.e., intestinal luminal) GSH in the recovery from 
fasting­induced intestinal mucosal atrophy enabled by 
oral GSH treatment have not yet been described.
A few studies have examined the ability of the 
extracellular thiol/disulfide redox state to regulate 
apoptosis and cell proliferation. Circu et al[16] de­
monstrated that the luminal/extracellular redox 
environment is determined by the cysteine/cystine 
(Cys/CySS) redox pair with contributions from the 
GSH system, with the majority of Cys in the intestinal 
lumen originating from GGT enzymatic hydrolysis of 
GSH obtained from dietary intake and biliary supply. 
Intestinal cell proliferation and apoptosis are associated 
with quantitative changes in the redox potential (Eh) 
of the extracellular GSH/GSSG or Cys/CySS redox 
pair. In the present study, the changes in apoptosis 
and cell proliferation in the intestinal mucosa resulting 
from oral GSH administration during fasting may 
derive from Eh changes mediated by GSH and Cys 
in the intestinal lumen, which in turn may ultimately 
control signaling proteins, enzyme catalysis, and 
gene expression. For example, Devadas et al[52] linked 
ROS formation with the progression of Fas­induced 
apoptosis via the protective effects of extracellular 
GSH, which are ascribed to its known capacity as 
an antioxidant. Specifically, extracellular GSH was 
deduced to inhibit Fas­mediated apoptosis following 
ROS reduction in cells because Fas crosslinking induced 
rapid generation of ROS well before the appearance of 
characteristic apoptotic changes. Furthermore, Fujise 
et al[22] suggested that fasting­induced apoptosis 
in the rat small intestine occurred via a receptor­
mediated type I apoptotic pathway including induced 
expression of FasL, Fas, and TNFR1. Selleri et al[53] 
and Viard­Leveugle et al[54] provided evidence that 
iNOS expression and NO production are involved in 
the mechanism of FasL upregulation and Fas­mediated 
apoptosis. The iNOS­NO­ROS­FasL pathway represents 
a potential link between the apoptosis and intestinal 
atrophy observed in the fasting.
In the present study, fasting­induced intestinal 
mucosal atrophy resulting from increased apoptosis 
was caused by increased production of NO and ROS 
as apoptosis mediators following elevation of iNOS 
expression. Because the iNOS­NO­ROS­FasL pathway 
is part of the apoptotic mechanism in the intestinal 
mucosa atrophy occurring after fasting[22,52­54], oral GSH 
treatment during fasting might inhibit Fas­mediated 
apoptosis following reduction of ROS levels in the 
jejunal mucosa resulting from Eh changes mediated 
by GSH and Cys in the intestinal lumen. Additionally, 
because iNOS protein expression was also induced by 
ROS produced from NO in fasting­induced intestinal 
mucosal atrophy in a previous study[20], the decrease 
in ROS levels in the intestinal mucosa reduces iNOS 
protein expression and NO production. Moreover, Jonas 
et al[55] showed that the extracellular thiol/disulfide 
redox state modulates cell proliferation and that this 
system interacted with growth factor signaling in a 
human colon carcinoma cell line. Thus, the change 
in extracellular thiol/disulfide redox state in response 
to peptide growth factors indicated an interaction of 
growth factor­activated pathways and thiol/disulfide 
metabolism during intestinal cell proliferation.
Therefore, oral GSH administration during fasting 
may regulate the redox state of the intestinal lumen 
and consequently may both relieve Fas­mediated 
apoptosis and increase growth factor­mediated cell 
proliferation by ROS removal in jejunal epithelial cells 
(Figure 11). However, because our present study 
focused on intracellular GSH, further studies focusing on 
extracellular GSH are required to confirm this model. In 
particular, a study utilizing measurements of GSH/GSSG 
and Cys/CySS levels in the intestinal lumen along with 
Fas and growth factor signaling in the jejunum may be 
necessary to identify the mechanism underlying the 
recovery of the intestinal mucosal atrophy mediated by 
oral GSH administration during fasting.
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In conclusion, oral GSH administration during fasting 
may provide regenerative potential to the jejunal 
mucosa through control of enterocyte apoptosis and cell 
proliferation. The GSH in the intestinal lumen provided 
through oral administration during fasting may not be 
involved in intracellular de novo GSH but may be useful 
to prevent intestinal mucosal atrophy by diminishing the 
levels of ROS in the jejunum generated by fasting.
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